Literature DB >> 11980564

The immunopathogenesis of paraneoplastic neurological syndromes.

Ian Sutton1, John B Winer.   

Abstract

Paraneoplastic neurological syndromes are rare non-metastatic complications of cancer that have an immune-mediated aetiology. The central and peripheral nervous systems are considered to be immune-privileged sites, since the presence of the 'blood-brain/nerve barrier' means that antigens sequestered within the nervous system do not normally induce an immune response. Aberrant expression of a neuronal antigen by a tumour arising outside this barrier can lead to the breakdown of immune tolerance to the nervous system. However, in many cases the immune mechanisms that result in neurological dysfunction remain poorly defined. Furthermore, aberrant expression of neuronal antigens can be detected in many tumours that are not complicated by non-metastatic neurological syndromes. This review article examines current concepts in the immunopathogenesis of paraneoplastic neurological syndromes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980564

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

1.  All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class.

Authors:  E Castillo-Gómez; B Oliveira; D Tapken; S Bertrand; C Klein-Schmidt; H Pan; P Zafeiriou; J Steiner; B Jurek; R Trippe; H Prüss; W-H Zimmermann; D Bertrand; H Ehrenreich; M Hollmann
Journal:  Mol Psychiatry       Date:  2016-08-09       Impact factor: 15.992

2.  Incidence and spectrum of paraneoplastic neurological syndromes: single center study.

Authors:  Meena A Kanikannan; Y Sirisha; Megha S Uppin; Sheik A Jabeen; Rukmini M Kandadai; Challa Sundaram; Digumarti Raghunadharao; Rupam Borgohain
Journal:  J Neurooncol       Date:  2015-08-27       Impact factor: 4.130

Review 3.  Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

Authors:  Meleeneh Kazarian; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2011-03-30       Impact factor: 27.401

4.  The great masquerader of malignancy: chronic intestinal pseudo-obstruction.

Authors:  Josephine A Taverna; Hani M Babiker; Seongseok Yun; Maria C Bishop; Sarah Lau-Braunhut; Paul N Meyer; Thomas Enzler
Journal:  Biomark Res       Date:  2014-12-05

5.  Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome with SOX-1 Antibodies.

Authors:  Shinichi Wada; Mayu Kamei; Naoko Uehara; Koji Tsuzaki; Toshiaki Hamano
Journal:  Intern Med       Date:  2020-12-15       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.